JP2006523711A5 - - Google Patents

Download PDF

Info

Publication number
JP2006523711A5
JP2006523711A5 JP2006510118A JP2006510118A JP2006523711A5 JP 2006523711 A5 JP2006523711 A5 JP 2006523711A5 JP 2006510118 A JP2006510118 A JP 2006510118A JP 2006510118 A JP2006510118 A JP 2006510118A JP 2006523711 A5 JP2006523711 A5 JP 2006523711A5
Authority
JP
Japan
Prior art keywords
composition
seq
composition according
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006510118A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006523711A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/011767 external-priority patent/WO2004093894A2/en
Publication of JP2006523711A publication Critical patent/JP2006523711A/ja
Publication of JP2006523711A5 publication Critical patent/JP2006523711A5/ja
Withdrawn legal-status Critical Current

Links

JP2006510118A 2003-04-17 2004-04-16 免疫調節因子としてのb7−h3の使用 Withdrawn JP2006523711A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46334203P 2003-04-17 2003-04-17
PCT/US2004/011767 WO2004093894A2 (en) 2003-04-17 2004-04-16 Use of b7-h3 as an immunoregulatory agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007095108A Division JP2007191489A (ja) 2003-04-17 2007-03-30 免疫調節因子としてのb7−h3の使用

Publications (2)

Publication Number Publication Date
JP2006523711A JP2006523711A (ja) 2006-10-19
JP2006523711A5 true JP2006523711A5 (enExample) 2007-05-24

Family

ID=33310770

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006510118A Withdrawn JP2006523711A (ja) 2003-04-17 2004-04-16 免疫調節因子としてのb7−h3の使用
JP2007095108A Withdrawn JP2007191489A (ja) 2003-04-17 2007-03-30 免疫調節因子としてのb7−h3の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007095108A Withdrawn JP2007191489A (ja) 2003-04-17 2007-03-30 免疫調節因子としてのb7−h3の使用

Country Status (14)

Country Link
US (1) US20050002935A1 (enExample)
EP (1) EP1620119A2 (enExample)
JP (2) JP2006523711A (enExample)
KR (1) KR20060017496A (enExample)
CN (1) CN1809370A (enExample)
AU (1) AU2004231748A1 (enExample)
BR (1) BRPI0409476A (enExample)
CA (1) CA2521847A1 (enExample)
CO (1) CO5700783A2 (enExample)
MX (1) MXPA05011050A (enExample)
NO (1) NO20054790L (enExample)
RU (1) RU2005135739A (enExample)
WO (1) WO2004093894A2 (enExample)
ZA (1) ZA200508367B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
US6965018B2 (en) 2000-06-06 2005-11-15 Bristol-Myers Squibb Company Antibodies directed to B7-related polypeptide, BSL-2
US20060241051A1 (en) 2002-12-26 2006-10-26 Chieko Kitada Metastin derivatives and use thereof
JP4346650B2 (ja) 2004-06-25 2009-10-21 武田薬品工業株式会社 メタスチン誘導体およびその用途
AR058584A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
JO3048B1 (ar) 2006-10-25 2016-09-05 Takeda Pharmaceuticals Co مشتقات متاستين واستخدامها
CA2668800A1 (en) * 2006-11-08 2008-06-05 Macrogenics West, Inc. Tes7 and antibodies that bind thereto
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
LT2703486T (lt) * 2011-04-25 2018-05-25 Daiichi Sankyo Company, Limited Anti-b7-h3 antikūnas
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
AU2015217278B2 (en) 2014-02-14 2020-03-19 Macrogenics, Inc. Improved methods for the treatment of vascularizing cancers
IL258521B2 (en) 2015-10-08 2024-01-01 Macrogenics Inc Combination therapy for the treatment of cancer
MY198114A (en) 2016-04-15 2023-08-04 Macrogenics Inc Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
WO2018177393A1 (zh) * 2017-03-31 2018-10-04 江苏恒瑞医药股份有限公司 B7-h3抗体、其抗原结合片段及其医药用途
CN109097366A (zh) * 2017-06-21 2018-12-28 黄海东 突变的人2Ig-B7-H3蛋白编码基因、重组载体、其药物组合物及其应用
US12312406B2 (en) 2018-11-09 2025-05-27 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Anti-B7-H3 antibody, preparation method therefor, conjugate and application thereof
JP7315703B2 (ja) * 2018-12-24 2023-07-26 ▲海▼▲東▼ 黄 組み換えヒト2Ig-B7-H3タンパク質コーディング遺伝子、組換えベクター及びそれを含む宿主細胞、並びに薬物組成物及びその応用
CN118878681A (zh) * 2019-07-18 2024-11-01 泰州复旦张江药业有限公司 一种抗b7-h3抗体及其制备方法、其偶联物和应用
CN111454357B (zh) * 2019-08-14 2022-03-15 康诺亚生物医药科技(成都)有限公司 一种含有抗体的肿瘤治疗剂的开发和应用
CN111088227A (zh) * 2019-12-31 2020-05-01 广州航华生物医药科技有限公司 一种细胞分离培养液和t细胞分离培养的方法
KR20230145038A (ko) 2021-02-09 2023-10-17 메디링크 테라퓨틱스 (쑤저우) 컴퍼니, 리미티드 생물활성 물질 접합체, 이의 제조방법 및 이의 용도
CN113144181B (zh) * 2021-04-20 2022-07-19 徐州医科大学 一种靶向b7h3的dna疫苗、制备方法及应用
EP4480499A1 (en) 2022-02-16 2024-12-25 Medilink Therapeutics (Suzhou) Co., Ltd. Conjugate of antibody-eribulin or derivative thereof, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and use thereof
CN119212733A (zh) 2022-05-18 2024-12-27 苏州宜联生物医药有限公司 包含蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途
CN120898001A (zh) * 2023-01-10 2025-11-04 上海仁又生基因技术有限公司 重组人2Ig-B7-H3蛋白编码基因、重组载体、宿主细胞、药物组合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6965018B2 (en) * 2000-06-06 2005-11-15 Bristol-Myers Squibb Company Antibodies directed to B7-related polypeptide, BSL-2
WO2002010187A1 (en) * 2000-07-27 2002-02-07 Mayo Foundation For Medical Education And Research B7-h3 and b7-h4, novel immunoregulatory molecules
AU2002347761A1 (en) * 2001-08-02 2003-02-24 Eli Lilly And Company Novel polypeptide analogs and fusions and their methods of use

Similar Documents

Publication Publication Date Title
JP2006523711A5 (enExample)
Kim et al. Regulatory T cells in tumor microenvironment and approach for anticancer immunotherapy
JP2022137020A (ja) 抗cd70キメラ抗原受容体
AU2025237926A1 (en) Nanoparticle compositions for sustained therapy
Miossec The Th1/Th2 cytokine balance in arthritis
JP2024026248A (ja) 多鎖キメラポリペプチドおよびその使用
ES2925307T3 (es) Receptores de linfocitos T que reconocen MAGE-A3 restringida al MHC de clase II
JP2004248677A5 (enExample)
Wiesel et al. Virus‐specific CD8 T cells: activation, differentiation and memory formation
JP2016502512A5 (enExample)
RU2005135739A (ru) Способ регулирования активации лимфоцита (варианты)
JP2010529860A5 (enExample)
JP2006507231A5 (enExample)
JP2015508757A5 (enExample)
JP2018029594A5 (enExample)
BR112019009477A2 (pt) moléculas de classe ii de pmhc recombinantes
WO2016154621A1 (en) SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
JP2010273685A5 (enExample)
AU2014407539A1 (en) Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation
WO2019104245A1 (en) Use and production of engineered immune cells
JP2016532693A5 (enExample)
JP2013505734A5 (enExample)
JP2013513377A5 (enExample)
JP2019513394A5 (enExample)
US20240010976A1 (en) Methods and compositions for stimulating gamma delta t cells